Last reviewed · How we verify
NCT03463902: GesttDCS
Transcranial Direct Current Stimulation (tDCS) to Improve Gesture Control
NA trial testing left IFG anodal in Schizophrenia and Related Disorders in 32 participants. Terminated before completion.
25 September 2023
Quick facts
| Lead sponsor | University of Bern |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 29 January 2018 |
| Primary completion | 25 September 2023 |
| Estimated completion | 22 March 2024 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- left IFG anodal
- left IFG cathodal
- left IPL anodal
- left IPL cathodal
- Placebo
Conditions studied
- Schizophrenia and Related Disorders — all drugs for Schizophrenia and Related Disorders →
Sponsor
University of Bern
Who can join
Adults 18 to 65, any sex, with Schizophrenia and Related Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The majority of schizophrenia patients is impaired in hand gesture performance, which contributes to poor functional outcome and poor communication skills. The left inferior frontal gyrus (IFG) and the left inferior parietal lobe (IPL) are key nodes of the gesture network, which is less active in patients with schizophrenia. Here, the investigators test single 10 min sessions of tDCS known to either enhance or inhibit local brain activity for app. 1 hour. The investigators aim to determine, which protocol may improve gesture performance in patients and healthy controls. This is a randomized, double-blind, cross-over, placebo-controlled single-center trial in 20 patients with schizophrenia spectrum disorders and 20 healthy controls. Gesture performance will be tested immediately after each tDCS session, which are separated by 24 hours. Results of this study will inform larger interventional trials comparing 2 tDCS protocols with repeated administration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03463902
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia and Related Disorders
Currently open trials in the same condition.
- NCT07378150 — Clay Therapy in Schizophrenia Patients · NA · recruiting
- NCT07119268 — SPARK Healthy Sleep · NA · recruiting
- NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
- NCT02916810 — Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment · NA · recruiting
- NCT06426134 — Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS · NA · recruiting
Other University of Bern trials
Trials by the same sponsor.
- NCT05940662 — Cost Effectiveness of Various Implant Placement Protocols in the Esthetic Zone · Phase 4 · suspended
- NCT02919163 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7) · NA · not yet recruiting
- NCT02919189 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7) · NA · not yet recruiting
- NCT04817592 — Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive · not yet recruiting
- NCT06806150 — The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03463902 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bern
- Last refreshed: 28 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03463902.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing